ERBB2 and neoplasm: Prior work within the National Comprehensive Cancer Network Breast Cancer Outcomes Database and in the Carolina Breast Cancer Study demonstrated that racial disparities vary by tumor subtype, with differences in survival between non-Hispanic Black and non-Hispanic White patients with HR+ BC and no differences for patients with triple negative or ERBB2+ BC.17,38 However, these patients were not exclusively clinical trial participants.